home - HK MoneyClub

Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases

TradingKey – Merck stock surged after its personalized mRNA cancer therapy met both Phase 3 melanoma endpoints. Strong Q2 sales and pipeline growth support MRK’s outlook.

Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases

All

Merck Stock Jumps on Phase 3 Cancer Vaccine Win as Keytruda Risk Eases

Does Gold Futures Trading Above Spot Really Signal a Bullish Market?

Today’s Market Recap：U.S. Treasury Steps In to Stabilize Markets,Stocks Rally, Bitcoin Breaks $70,000, Moderna Surges 180%

Japanese and South Korean Stocks Rebound in Early Trade, KOSPI Rises Over 3%, SK Hynix Surges Over 8%, Samsung Gains Over 5%

Wolfspeed (WOLF) Q4 FY2026 Earnings Call: AI Data Center Revenue Doubles

BILL Q4 FY2026 Earnings Call: AI Adoption and 23% Non-GAAP Margin

Webull (BULL) Q2 2026 Earnings Call: Revenue Rises 51% as PDT Change Lifts Trading

Beam Global (BEEM) Q2 2026 Earnings Call: Revenue Rises 174% Sequentially

Klarna (KLAR) Q2 2026 Earnings Call: Margin Outlook Raised Despite Lower GMV Guidance

Antalpha (ANTA) Q2 2026 Earnings Call: Revenue Falls as Gold Marks Weigh

Accuray (ARAY) Fiscal Q4 2026 Earnings Call: Service Growth, Product Revenue Decline

Coty Q4 FY2026 Earnings: Sales Return to Growth as Margins Contract

Nordson Fiscal Q3 2026 Earnings: Advanced Technology Drives 10% Sales Growth

UNIFI Fiscal Q4 2026 Earnings: Gross Margin Rebounds to 9.9%

Webull Q2 2026 Earnings: Record Trading Volumes Drive 51% Revenue Growth